Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Complex, Less Debilitating Treatment for Neuroendocrine Cancer Now Available in Israel at Hadassah

hMedicine

Dr. Asher Salmon, Senior Oncologist, Hadassah's Sharett Institute of Oncology

A treatment for neuroendocrine cancer that was previously only available abroad is now being provided at the Hadassah University Medical Center. Patients are injected with radioactive material that attaches to the malignant cell, absorbing and destroying it with minimal damage to other tissue. The new treatment is the outgrowth of three years of collaboration between Hadassah and Israel's Soreq Nuclear Research Center, an applied research and development institute affiliated with the Israel Atomic Energy Commission. The radioactive material is assembled at the Soreq Center and sent to Hadassah once a week at a set time.

Based on the fact that these endocrine tumors have an increased ability to absorb a hormone called somatostatin, the therapeutic procedure involves attaching a similar molecule to the hormone which is, in turn, attached to a radioactive atom. The atom binds to receptors on the outer membrane of the tumor and is absorbed into the malignant cell, emitting ionizing radiation which destroys it.

According to Dr. Asher Salmon, Senior Oncologist at Hadassah's Sharett Institute of Oncology, the treatment successfully prolongs life expectancy for 80 percent of patients and retards the progress of the disease for 50 percent. "This treatment, considered one of the best and most innovative available, differs from chemotherapy, providing prolonged relief for the patients with only a few side effects," he says. Following just one day in the hospital, patients are sent home; within several days, they can resume their normal lives.

Hadassah's departments of endocrinology, oncology, nuclear medicine, and radiology collaborate in providing this treatment to Hadassah's patients.

Date: 2/15/2012


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America